Section Arrow
Quote
MPLT.NASDAQ
- MapLight Therapeutics Inc.
Quotes are at least 15-min delayed:2026/09/04 05:53 EDT
Pre Market
Last
 12.81
-0.33 (-2.51%)
Bid
11.4
Ask
15.88
High 13.14 
Low 12.81 
Volume 68 
Regular Hours (Closed)
Last
 13.14
+0.08 (+0.61%)
Day High 
13.45 
Prev. Close
13.06 
1-M High
13.9399 
Volume 
863.54K 
Bid
11.4
Ask
15.88
Day Low
12.96 
Open
13.2 
1-M Low
10.51 
Market Cap 
605.69M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 12.37 
20-SMA 12.16 
50-SMA 22.85 
52-W High 40.43 
52-W Low 9.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-19.96/-4.58
Enterprise Value
610.61M
Balance Sheet
Book Value Per Share
7.51
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.85-11.68-44.03%-- 
Pre Market 14.99 +0.14 +0.94%
AIMAIM ImmunoTech Inc.0.2337-0.0009-0.38%-- 
Pre Market 0.234 +0.0003 +0.13%
ATAIAtaiBeckley Inc7.34-0.01-0.14%-- 
Pre Market 7.31 -0.03 -0.41%
SMMTSummit Therapeutics17.13+2.53+17.33%-- 
Pre Market 16.8657 -0.2643 -1.54%
IOVAIovance Biotherapeutics8.7+0.08+0.93%-- 
Pre Market 8.725 +0.025 +0.29%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.